Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00433433
Status:
UNKNOWN
Last Update Posted:
2021-02-03
First Post:
2007-02-08
Brief Title:
Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkins Lymphoma
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
European Organisation for Research and Treatment of Cancer - EORTC
Study Overview
Official Title:
The H10 EORTCGELAIIL Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Supradiaphragmatic Stage III Hodgkins Lymphoma
Status:
UNKNOWN
Status Verified Date:
2021-02
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
H10
Brief Summary:
RATIONALE Drugs used in chemotherapy work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing Giving more than one drug combination chemotherapy may kill more cancer cells Diagnostic procedures such as fludeoxyglucose F 18 positron emission tomography FDG-PET scan may help doctors predict a patients response to treatment and help plan the best treatment It is not yet known whether FDG-PET scan-guided therapy is more effective than standard therapy in treating Hodgkins lymphoma
PURPOSE This randomized phase III trial is studying FDG-PET scan-guided therapy to see how well it works compared with standard therapy in treating patients with previously untreated stage I or stage II Hodgkins lymphoma
PURPOSE This randomized phase III trial is studying FDG-PET scan-guided therapy to see how well it works compared with standard therapy in treating patients with previously untreated stage I or stage II Hodgkins lymphoma
Detailed Description:
OBJECTIVES
Primary
Evaluate whether chemotherapy alone is as effective but less toxic as combined modality treatment in terms of progression-free survival PFS in patients with favorable or unfavorable supradiaphragmatic stage I or II Hodgkins lymphoma who are fludeoxglucose F 18 positron emission tomography FDG-PET scan negative after two courses of doxorubicin hydrochloride bleomycin vinblastine and dacarbazine ABVD
Secondary
Evaluate whether early change of chemotherapy from ABVD to escalated cyclophosphamide doxorubicin hydrochloride vincristine bleomycin etoposide procarbazine hydrochloride and prednisone escalated BEACOPP improves the PFS of patients who are FDG-PET scan positive after two courses of ABVD
Confirm that early response by FDG-PET scan is predictive of the outcome of patients randomized to the standard treatment arm
OUTLINE This is a multicenter randomized study Patients are stratified according to disease prognostic profile favorable vs unfavorable participating center Ann Arbor clinical stage I vs II and availability of a baseline fludeoxyglucose F 18 positron emission tomography FDG-PET scan yes vs no Patients are randomized to 1 of 2 treatment arms
Arm I standard closed to accrual as of 6242011 Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV bleomycin IV or intramuscularly IM vinblastine IV and dacarbazine IV on days 1 and 15 Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity Patients with favorable prognostic profile receive 3 courses of ABVD Patients with unfavorable prognostic profile receive 4 courses of ABVD Patients undergo FDG-PET scan after completion of 2 courses of ABVD Beginning 3-4 weeks after completion of ABVD patients undergo involved-node radiotherapy INRT 5 days a week for 4-6 weeks
Arm II experimental Patients receive ABVD as in arm I for 2 courses and then undergo FDG-PET scan Further treatment is adapted according to FDG-PET scan result
FDG-PET negative Patients with favorable prognostic profile receive 1 additional courses of ABVD Patients with unfavorable prognostic profile receive 2 additional courses of ABVD Patients with favorable or unfavorable prognostic profiles randomized on or after August 9th 2010 who are FDG-PET negative after two courses of ABVD will receive standard combined modality treatment consisting of ABVD and INRT as in arm I
FDG-PET positive Patients receive ABVD as in arm I for 2 courses or intensification to escalated BEACOPP chemotherapy comprising cyclophosphamide IV and doxorubicin hydrochloride IV on day 1 vincristine IV and bleomycin IV or IM on day 8 etoposide IV on days 1-3 oral procarbazine hydrochloride on days 1-7 oral prednisone on days 1-14 and filgrastim G-CSF subcutaneously beginning on day 9 and continuing until blood count recover Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity Beginning 3-4 weeks after completion of ABVD or BEACOPP patients undergo INRT 5 days a week for 4-6 weeks
After completion of study treatment patients are followed periodically for at least 10 years
PROJECTED ACCRUAL A total of 1797 patients will be accrued for this study
Primary
Evaluate whether chemotherapy alone is as effective but less toxic as combined modality treatment in terms of progression-free survival PFS in patients with favorable or unfavorable supradiaphragmatic stage I or II Hodgkins lymphoma who are fludeoxglucose F 18 positron emission tomography FDG-PET scan negative after two courses of doxorubicin hydrochloride bleomycin vinblastine and dacarbazine ABVD
Secondary
Evaluate whether early change of chemotherapy from ABVD to escalated cyclophosphamide doxorubicin hydrochloride vincristine bleomycin etoposide procarbazine hydrochloride and prednisone escalated BEACOPP improves the PFS of patients who are FDG-PET scan positive after two courses of ABVD
Confirm that early response by FDG-PET scan is predictive of the outcome of patients randomized to the standard treatment arm
OUTLINE This is a multicenter randomized study Patients are stratified according to disease prognostic profile favorable vs unfavorable participating center Ann Arbor clinical stage I vs II and availability of a baseline fludeoxyglucose F 18 positron emission tomography FDG-PET scan yes vs no Patients are randomized to 1 of 2 treatment arms
Arm I standard closed to accrual as of 6242011 Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV bleomycin IV or intramuscularly IM vinblastine IV and dacarbazine IV on days 1 and 15 Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity Patients with favorable prognostic profile receive 3 courses of ABVD Patients with unfavorable prognostic profile receive 4 courses of ABVD Patients undergo FDG-PET scan after completion of 2 courses of ABVD Beginning 3-4 weeks after completion of ABVD patients undergo involved-node radiotherapy INRT 5 days a week for 4-6 weeks
Arm II experimental Patients receive ABVD as in arm I for 2 courses and then undergo FDG-PET scan Further treatment is adapted according to FDG-PET scan result
FDG-PET negative Patients with favorable prognostic profile receive 1 additional courses of ABVD Patients with unfavorable prognostic profile receive 2 additional courses of ABVD Patients with favorable or unfavorable prognostic profiles randomized on or after August 9th 2010 who are FDG-PET negative after two courses of ABVD will receive standard combined modality treatment consisting of ABVD and INRT as in arm I
FDG-PET positive Patients receive ABVD as in arm I for 2 courses or intensification to escalated BEACOPP chemotherapy comprising cyclophosphamide IV and doxorubicin hydrochloride IV on day 1 vincristine IV and bleomycin IV or IM on day 8 etoposide IV on days 1-3 oral procarbazine hydrochloride on days 1-7 oral prednisone on days 1-14 and filgrastim G-CSF subcutaneously beginning on day 9 and continuing until blood count recover Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity Beginning 3-4 weeks after completion of ABVD or BEACOPP patients undergo INRT 5 days a week for 4-6 weeks
After completion of study treatment patients are followed periodically for at least 10 years
PROJECTED ACCRUAL A total of 1797 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EU-20657 | None | None | None |
| EORTC-20051 | None | None | None |
| GELA-H10 | None | None | None |
| IIL-EORTC-20051 | None | None | None |
| EUDRACT-2005-002765-37 | None | None | None |